Introduction
============

Worldwide, cancer still ranks the number one killer that threatens people\'s life. Approximately 14.1 million new cancer cases and 8.2 million cancer-caused deaths occurred globally in 2013 [@B1]. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States [@B2]. By now, the definitive etiology of cancer remains unknown. However, a myriad of evidence has suggested that cancer is a complex disease caused by both genetic and environmental factors [@B3], [@B4]. Numerous functional polymorphisms have been found to be implicated in the development of cancers [@B5]-[@B7].

Previous researches have reported that hormonal factors play crucial roles in the development of some cancers. Common genetic variants in hormonal-related genes were associated with cancer susceptibility [@B8]. Among them, estrogen receptor (ER) was the most related-hormone in cancer risk. Estrogen receptor (ER) has two forms, which is alpha and beta [@B9]. Estrogen receptor-α plays a critical role in mediating hormonal response in estrogen-sensitive tissues. It consists of several domains important for hormone regulation, activation of transcription and DNA binding. Evidence points to estrogen receptor-α as the main receptor correlated to initiation of cancer [@B10]. Estrogen receptor-α, a transcription factor, is encoded by the *ESR1* gene.

The *ESR1* gene, comprises of 8 exons and 7 introns, is located on chromosome 6q25.1. Several SNPs of *ESR1* gene have been identified to influence the risk of cancer, but the most popular studied SNP is *ESR1* PvuII (rs2234693 T\>C) polymorphism [@B11]. Although increasing studies have been performed, the conclusions of the roles of *ESR1* PvuII (T\>C) polymorphism in cancer risk are conflicting. The inconsistent conclusions between *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk may be due to the limitations in the sample size of the corresponding studies or the inadequate statistical power in genetic studies with complex characteristics. Several meta-analyses regarding this issue have been performed to resolve the conflicting situation but somehow failed. With the aim to solve such embarrassment, we conducted this comprehensive meta-analysis by adopting all published articles.

Materials and methods
=====================

Publication search
------------------

We first inputted the following key words: "single nucleotide polymorphism or polymorphism or variant or SNP" and "*ESR1* or *ESR*α or Estrogen Receptor α or Estrogen Receptor 1", and "cancer or tumor or neoplasm or carcinoma)" in database of PubMed and EMBASE. In addition, we also searched the Chinese database CNKI and WANFANG to include more eligible studies. Further, additional studies were also manually extracted from the references of the above obtained publications. The date of the final literature search was set on January 2018. We did not set any language publication restrictions here. The article will be considered as different studies if it contains more than two ethnicities. If the searched articles have overlapping data, the largest one will be selected.

Eligibility criteria
--------------------

The evaluating publications in this meta-analysis should fulfill all the following requirements: 1) unrelated case-control studies; 2) original epidemiological studies; 3) analyzing the relationship between *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk; 4) enough data to obtain odds ratios (ORs) and 95% confidence intervals (CIs); 5) articles written in English or in Chinese.

Data extraction
---------------

Two authors separately extracted data by screening all eligible studies. They collected the information regarding first author\'s surname, country, publication year, ethnicity, genotyping methods, the source of controls, and numbers of cases and controls with CC, CT and TT genotypes. All the disagreed information was settle down after fully discussed by the two authors.

Statistical methods
-------------------

Hardy-Weinberg equilibrium (HWE) in the controls was determined using goodness-of-fit χ^2^ test. *P*\<0.05 was considered as departure from HWE. Three genetic models, homozygous model (TT vs. CC), heterozygous model (TT vs. CT), and allele comparison (T vs. C), were applied to assess the association between *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk. The strength of such association was assessed by calculating ORs with the corresponding 95% CIs. Stratification analyses were also conducted by ethnicity, cancer type, source of control, and HWE in controls, in all studies. Chi square-based *Q*-test was adopted to monitor between-study heterogeneity. The fixed-effects model (the Mantel-Haenszel method) was chosen to estimate the pooled OR, if the studies were homogeneous (*P*\>0.10 for the*Q* test). Otherwise, the random-effects model (the DerSimonian and Laird method) was used. Sensitivity analysis was conducted by excluding each study individually and re-calculating the ORs and 95% CIs. Begg\'s funnel plot and Egger\'s linear regression were used to evaluate whether there exists publication bias [@B12], [@B13]. The asymmetric plot and *P* value less than 0.5 was considered as the existence of publication bias. We also conducted quality assessment to detect the quality of each study using the quality assessment criteria [@B14]. The version 11.0 STATA software was adopted to perform all statistical analysis (Stata Corporation, College Station, TX). All the statistics were two-sided with *P* value of \<0.05 as significant findings.

Results
=======

Study characteristics
---------------------

Our first research in databases identified 185 candidate publications. After screening the title and abstract, we kept 64 publication s in the analysis [@B15]-[@B78]. Moreover, we further extracted 5 articles from the references of the retrieval articles [@B79]-[@B83]. The flow chart of screening process was graphically shown in **Figure [1](#F1){ref-type="fig"}**. In final, 80 studies (69 publications) with 26428 cases and 43381 controls were included in the pooled analysis (**Table [1](#T1){ref-type="table"}**). Among them, 38 studies focused on Asians, 36 on Caucasians, 3 on Africans, 1 on Hispanics and 1 on non-Hispanic Caucasians, 1 on Hispanic Caucasians. 44 studies were hospital-based design, 36 were population-based design. The controls\' genotype frequencies were in agreement with HWE (*P*\>0.05) in 74 studies, except for 6 studies.

Meta-analysis results
---------------------

The summary results of meta-analysis were presented in **Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**. In all, no significant association between the *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk was observed under homozygous model (TT vs. CC: OR=0.92, 95% CI=0.84-1.01) and heterozygous model (TT vs. CT: OR=0.94, 95% CI=0.88-1.001). Statistically significant relationship was only observed for PvuII in allele model T vs. C (OR=0.95, 95% CI=0.91-0.99).

In subgroup analysis by cancer type, we found that the T genotype significantly decreased prostate cancer risk (TT vs. CC: OR=0.79, 95% CI=0.66-0.94; T vs. C: OR=0.89, 95% CI=0.82-0.98), Leiomyoma risk (T vs. C: OR=0.82, 95% CI=0.68-0.98), and HCC risk (TT vs. CC: OR=0.45, 95% CI=0.28-0.71; T vs. C: OR=0.67, 95% CI=0.47-0.95). However, no relationship between *ESR1* PvuII polymorphism and any other types of cancer was observed. Ethnicity subgroup analysis revealed that significant association between *ESR1* PvuII genotype and cancer risk was detected among African (TT vs. CC: OR=0.54, 95% CI=0.30-0.98), and Hispanics (TT vs. CT: OR=0.41, 95% CI=0.17-0.99; T vs. C: OR=0.55, 95% CI=0.30-0.99). Such association was not observed for the Asians and Caucasians. In terms of source of controls, we found that the *ESR1* PvuII T genotype help to decrease cancer risk in hospital-based group (T vs. C: OR=0.89, 95% CI=0.83-0.96) and in population-based group (TT vs. CC: OR=0.81, 95% CI=0.70-0.94; TT vs. CT: OR=0.86, 95% CI=0.78-0.96). Further subgroup analysis by HWE in controls also failed to detect positive association, except for heterogenous model in HWE\>0.05 subgroup (TT vs. CT: OR=0.94, 95% CI=0.88-1.00). Subgroup analysis of quality revealed that *ESR1* PvuII T genotype help to decrease cancer risk in group with quality score ≤9.

Heterogeneity and sensitivity analysis
--------------------------------------

Between-study heterogeneity was first calculated by using *Q* test and *I^2^* statistics. We used the random-effect model as significant heterogeneity was observed among all three genetic models (*P*\<0.001) in the pooled analysis (TT vs. CC: *P*\<0.001, I^2^ = 59.1%; TT vs. CT: *P*\<0.001, I^2^ = 49.4%; T vs. C: *P*\<0.001, I^2^ = 61.0%). In addition, sequential leave-one-out sensitivity analysis was adopted to evaluate the stability of the results. After removing each study, no substantial changes in pooled results were found (**Figure [3](#F3){ref-type="fig"}**).

Publication bias
----------------

The shape of Begg\'s funnel plots was quite symmetry (**Figure [4](#F4){ref-type="fig"}**). Moreover, statistical evidence of Egger\'s test also provided the none-existence of publication bias among the studies (data not shown).

Discussion
==========

In this meta-analysis, we comprehensively evaluated the association between *ESR1* PvuII (rs2234693 T\>C) polymorphism with cancer susceptibility. The obtained results suggested *ESR1* PvuII (rs2234693 T\>C) polymorphism may influence overall cancer risk in a low impact effect manner. So far, this meta-analysis represents the most powerful investigation in elucidating the role of *ESR1* PvuII (rs2234693 T\>C) in cancer risk.

The polymorphism of *ESR1,* PvuII (rs2234693 T\>C), can affect *ESR1* transcription activity and further contribute to the carcinogenesis. A myriad of studies has investigated the role of *ESR1* PvuII (rs2234693 T\>C) polymorphisms in cancer risk. In 2001, Massart et al. claimed that the PvuII and XbaI polymorphisms in the *ESR1* gene do not produce different risks of developing uterine leiomyomas [@B52]. In another study performed in urban Shanghai with 1069 breast cancer patients and 1166 controls, Cai et al. found that *ESR1* PvuII (rs2234693 T\>C) polymorphism conferred to an enhanced risk of breast cancer among subjects carrying Pp (CT) and pp (TT) genotypes [@B21]. Yet, AI-Hendy et al. claimed that the *ESR1*PvuII PP (CC) genotype contributed to a significantly increased risk of uterine leiomyomas in black and white women, but not in Hispanic women [@B15]. Many meta-analyses have been conducted aiming to obtain a clear association between *ESR1* PvuII (rs2234693 T\>C) and cancer risk. In 2010, Li et al. performed a meta-analysis regarding the association of several potentially functional SNPs in *ESR1* with breast cancer risk. This analysis on 10,300 breast cancer cases and 16,620 controls in PvuII (rs2234693 T\>C) polymorphism revealed a borderline significant decreased breast cancer risk for CC and CC/CT carriers (CC vs. TT: OR=0.92, 95% CI=0.86-0.99; CC/CT vs. TT: OR=0.95, 95% CI=0.89-1.00) [@B84]. In a meta-analysis updated to April 2014, 41 studies were included to analyze the relationship between *ESR1* PvuII (rs2234693 T\>C) and cancer risk. Results of the pooled analysis suggested a null relationship between PvuII (rs2234693 T\>C) polymorphism and overall cancer risk. Subgroup analysis indicated that PvuII (rs2234693 T\>C) polymorphism was associated with a decreased risk of gallbladder cancer, in contrast with the increased risk of prostate cancer and hepatocellular carcinoma (HCC). They also failed to observe significant association in Asian and Caucasian populations [@B85].

From then on, several new case-control studies with larger samples were available. In addition, the former meta-analysis conducted only included studies published in English. To provide a robust clarification, we performed the updated meta-analysis by involving all the eligible studies published. Overall, statistically significant relationship was only observed for PvuII in allele model T vs. C (OR=0.95, 95% CI=0.91-0.99). However, we did not detect any significant relationship between *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk in the pooled analysis under homozygous and heterozygous model. Cancer type by subgroup analysis indicated that T genotype significantly decreased prostate cancer risk, Leiomyoma risk, and HCC risk. Yet no association was observed in other types of cancers. These data suggested that the PvuII (rs2234693 T\>C) polymorphism on *ESR1* may function in a wide manner regarding the different cancer types. When stratified by population, no significant association between *ESR1* PvuII genotype and cancer risk among African, and Hispanics was detected. Such association was observed for the Africans. The limited statistical power caused by relatively small number of studies in Africans should be considered. In this meta-analysis, several measurements were performed to enhance the credibility of our conclusion. First, we adopted every effort to expand the numbers of included studies, such as incorporating all publications written both in Chinese and in English. The relatively large number of including studies was one of the important merits of the current study. We also performed publication bias and the sensitivity analysis under the guidance of Cochrane protocol. The sensitivity analysis and publication bias analysis revealed the strength of our conclusions. Although this meta-analysis has its own merits, limitations still exist. First, we only used unadjusted estimates to determine whether there is a relationship between *ESR1* PvuII (rs2234693 T\>C) polymorphism and cancer risk. Adjustment analysis was absence due to the lack of patient\'s clinical data such as life habit, smoking and drinking status, exposing factors, and gene-environment interactions, which restrains our further analysis for confounding factors. Second, the validity of conclusion was impaired as significant between-study heterogeneity was detected in some comparisons. Such heterogeneity might result from different quality of studies, and might impair the strength of the conclusion. Third, selection bias and language bias were inevitable, as only published studies and papers written in English or Chinese were analyzed, respectively. Moreover, selection bias might also generate as most of the studies included in this meta-analysis were from candidate gene based, but not from GWAS. Fourth, the sample size of subgroup analysis was relatively small in some strata, impaired the statistical power to estimate the real association. Last, the analyzed case-control studies were mostly performed using Caucasians and Asians populations. Therefore, more trials using different population background, especially Africans, are essential to further confirm such conclusion, due to the genetic and geographical differences.

Conclusion
==========

In conclusion, the current meta-analysis suggests that *ESR1* PvuII (rs2234693 T\>C) polymorphism may not be strong enough to impact the risk of cancer, based on the pooled results of the published articles. Such relationship further helps to explain the etiology of cancer. Yet, further epidemiological studies with larger sample sizes, standardized unbiased design are warranted to confirm this conclusion.
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###### 

The baseline characteristics of all qualified studies in this meta-analysis

  Surname            Year   Country       Ethnicity                 Cancer type   Control Source   Genotype method   Case   Control   HWE   Score                                       
  ------------------ ------ ------------- ------------------------- ------------- ---------------- ----------------- ------ --------- ----- ------- ------ ------ ------ ------ ------- ----
  Modugno            2001   USA           Caucasian                 Prostate      PB               PCR               26     34        21    81      85     109    43     237    0.438   8
  Massart            2001   Italy         Caucasian                 Leiomyoma     HB               PCR               35     57        27    119     46     77     33     156    0.941   5
  Suzuki             2003   Japan         Asian                     Prostate      PB               PCR               46     43        12    101     29     59     26     114    0.702   9
  Massart            2003   Italy         Caucasian                 Leiomyoma     HB               PCR-RFLP          54     91        43    188     66     111    48     225    0.917   5
  Iwamoto            2003   Japan         Asian                     Endometrial   HB               PCR-RFLP          25     54        13    92      25     28     12     65     0.408   4
  Shin               2003   Korea         Asian                     Breast        PB               PCR-RFLP          75     91        35    201     64     105    26     195    0.095   8
  Tanaka             2003   Japan         Asian                     Prostate      HB               PCR               23     63        29    115     39     113    48     200    0.061   6
  Cai                2003   China         Asian                     Breast        PB               PCR-RFLP          415    516       138   1069    430    546    190    1166   0.452   12
  Fukatsu            2004   Japan         Asian                     Prostate      HB               PCR-RFLP          37     57        22    116     81     110    47     238    0.384   6
  wedren             2004   Sweden        Caucasian                 Breast        PB               PCR-RFLP          390    634       268   1292    384    651    313    1348   0.248   10
  Lu                 2005   China         Asian                     Breast        HB               PCR-RFLP          54     65        19    138     50     69     21     140    0.723   78
  Modugno            2005   USA           Caucasian                 Breast        PB               PCR-RFLP          53     115       80    248     819    1810   1272   3901   0.000   6
  Onland-Moret       2005   Netherlands   Caucasian                 Breast        PB               PCR-RFLP          89     150       69    308     88     153    96     337    0.093   9
  Low                2006   UK            Caucasian                 Prostate      PB               TaqMan            13     41        21    75      49     84     25     158    0.266   2
  Al-Hendy           2006   USA           African                   Leiomyoma     HB               PCR-RFLP          22     34        36    92      9      9      3      21     0.760   3
  Al-Hendy           2006   USA           Caucasian                 Leiomyoma     HB               PCR-RFLP          21     23        17    61      57     99     1      157    0.000   2
  Al-Hendy           2006   USA           Hispanic                  Leiomyoma     HB               PCR-RFLP          14     23        8     45      27     18     6      51     0.284   11
  Zhai               2006   China         Asian                     HCC           PB               PCR-RFLP          74     117       53    244     91     116    30     237    0.457   6
  Chen               2006   China         Asian                     Leiomyoma     HB               PCR-RFLP          35     37        11    83      31     38     9      78     0.604   5
  Denschlag          2006   Germany       Caucasian                 Leiomyoma     PB               PCR               33     66        31    130     40     59     40     139    0.075   9
  Hernandez          2006   USA           Caucasian                 Prostate      PB               TaqMan            47     55        18    120     129    131    43     303    0.300   11
  Hernandez          2006   USA           Caucasian                 Prostate      PB               TaqMan            115    216       100   431     154    296    132    582    0.653   9
  Hernandez          2006   USA           African                   Prostate      PB               TaqMan            9      22        16    47      50     113    50     213    0.373   11
  Shen               2006   China         Asian                     Breast        PB               PCR-RFLP          98     120       29    247     107    124    43     274    0.480   10
  Cunningham         2007   Minnesota     Caucasian                 Prostate      PB               PCR               257    454       213   924     120    249    120    489    0.684   9
  Berndt             2007   USA           Caucasian                 Prostate      HB               PCR               121    238       111   470     152    316    135    603    0.230   9
  Hsieh              2007   China         Asian                     Leiomyoma     PB               PCR-RFLP          25     75        6     106     60     44     6      110    0.571   7
  Hu                 2007   China         Asian                     Breast        HB               PCR-RFLP          39     58        16    113     49     45     19     113    0.128   7
  Kadiyska           2007   Bulgaria      Caucasian                 Colorectal    HB               PCR-RFLP          34     79        27    140     23     35     19     77     0.438   11
  Kjaergaard         2007   Danmark       Caucasian                 Prostate      PB               TaqMan            35     55        26    116     1203   1972   830    4005   0.676   11
  Kjaergaard         2007   Danmark       Caucasian                 Breast        PB               TaqMan            398    613       245   1256    727    1225   537    2489   0.621   7
  Wang               2007   USA           Caucasian                 Breast        PB               PCR               117    188       87    392     214    393    176    783    0.862   4
  Onsory             2008   India         Asian                     Prostate      HB               PCR-RFLP          28     54        18    100     42     48     10     100    0.487   
  González-Mancha    2008   Spain         Caucasian                 Breast        PB               PCR-RFLP          153    209       82    444     193    361    150    704    0.435   6
  Sobti              2008   India         Asian                     Prostate      HB               PCR               52     77        28    157     64     90     16     170    0.050   6
  Gonzalez-Zuloeta   2008   Netherlands   Caucasian                 Breast        PB               PCR-RFLP          72     94        24    190     1602   1648   453    3703   0.359   6
  Dunning            2009   UK            Caucasian                 Breast        PB               TaqMan            1260   2164      938   4362    1318   2296   934    4548   0.253   8
  Ashton             2009   Australia     Caucasian                 Endometrial   PB               PCR-RLFP          39     95        57    191     96     129    65     290    0.088   11
  Iwasaki            2009   Japan         Asian                     Breast        HB               TaqMan            144    180       64    388     115    196    77     388    0.692   10
  Iwasaki            2009   Japan         Asian                     Breast        HB               TaqMan            25     39        15    79      22     43     14     79     0.374   9
  Iwasaki            2009   Japan         Asian                     Breast        HB               TaqMan            107    187       85    379     122    194    63     379    0.338   10
  Sonestedt          2009   Sweden        Caucasian                 Breast        PB               MassARRAY         158    273       108   539     316    539    218    1073   0.667   10
  Beuten             2009   USA           non-Hispanic Caucasians   Prostate      PB               PCR               167    304       138   609     222    421    200    843    0.988   7
  Beuten             2009   USA           Hispanic Caucasians       Prostate      PB               PCR               75     92        28    195     186    246    82     514    0.964   7
  Beuten             2009   USA           African                   Prostate      PB               PCR               18     41        23    82      54     105    50     209    0.940   7
  Anghel             2009   Romania       Caucasian                 Bladder       HB               PCR               0      6         9     15      18     48     48     114    0.309   5
  Anghel             2009   Romania       Caucasian                 Colorectal    HB               PCR               2      13        3     18      18     48     48     114    0.309   5
  Anghel             2009   Romania       Caucasian                 AML           HB               PCR               0      5         10    15      18     48     48     114    0.309   5
  Anghel             2009   Romania       Caucasian                 HCC           HB               PCR               2      6         4     12      18     48     48     114    0.309   5
  Anghel             2009   Romania       Caucasian                 Breast        HB               PCR               4      65        32    101     15     38     37     90     0.333   6
  Wang JY            2010   China         Asian                     Leiomyoma     HB               PCR-RFLP          24     46        22    92      51     100    42     193    0.592   6
  Wang XL            2010   China         Asian                     Leiomyoma     HB               PCR-RFLP          42     48        12    102     35     49     16     100    0.867   6
  Gupta              2010   India         Asian                     Prostate      HB               PCR-RFLP          52     77        28    157     64     90     16     170    0.049   6
  Park               2010   China         Asian                     Gallbladder   PB               PCR-RFLP          41     100       94    235     108    356    314    778    0.658   11
  Sonoda             2010   Japan         Asian                     Prostate      HB               PCR               60     89        31    180     61     87     29     177    0.828   5
  Sakoda             2011   China         Asian                     Breast        PB               PCR               229    290       93    612     327    427    120    874    0.298   12
  Deng               2011   China         Asian                     Breast        HB               PCR-RFLP          42     63        23    128     52     61     17     130    0.892   7
  Wang               2011   China         Asian                     Cervical      HB               PCR-RFLP          39     45        18    102     32     52     18     102    0.692   6
  Sissung            2011   USA           Caucasian                 Prostate      PB               TaqMan            25     75        28    128     46     60     20     126    0.952   3
  de Giorgi          2011   Italy         Caucasian                 Melanoma      HB               PCR-RFLP          32     49        31    112     56     98     41     195    0.876   6
  Balistreri         2011   Italy         Caucasian                 Prostate      HB               PCR-RFLP          37     11        2     50      84     7      0      91     0.702   4
  Han                2011   China         Asian                     Breast        PB               TaqMan            353    399       107   859     324    402    151    877    0.171   9
  Szendroi           2011   Hungary       Caucasian                 Prostate      HB               PCR-RFLP          43     122       39    204     31     47     25     103    0.392   7
  Lundie             2012   USA           Caucasian                 Endometrial   PB               PCR               116    184       91    391     194    369    146    709    0.223   9
  Srivastava         2012   India         Asian                     Gallbladder   PB               PCR-RFLP          59     218       133   410     19     110    91     220    0.075   12
  Safarinejad        2012   Iran          Asian                     Prostate      PB               PCR-RFLP          11     94        57    162     65     169    90     324    0.373   6
  Chang              2012   China         Asian                     Lung          HB               PCR-RFLP          21     60        3     84      62     132    40     234    0.034   4
  Tang               2013   China         Asian                     Breast        HB               MALDI-TOF         293    374       127   794     334    375    136    845    0.076   9
  Jurecekova         2013   Slovak        Caucasian                 Prostate      HB               PCR               78     154       79    311     81     126    49     256    1       5
  Pazarbasi          2013   Turkey        Caucasian                 Prostate      HB               PCR               14     14        6     34      10     7      10     27     0.012   3
  Ramalhinho         2013   Portugal      Caucasian                 Breast        HB               PCR-RFLP          28     60        19    107     45     60     16     121    0.566   7
  Liu                2014   China         Asian                     HCC           HB               PCR               34     54        19    107     57     38     10     105    0.331   6
  Chattopadhyay      2014   India         Asian                     Breast        PB               PCR-RFLP          157    164       39    360     136    162    62     360    0.252   11
  Lu                 2014   China         Asian                     Breast        HB               PCR-RFLP          227    258       57    542     425    454    137    1016   0.368   5
  Madeira            2014   Brazil        Asian                     Breast        HB               PCR-RFLP          6      49        9     64      25     39     8      72     0.211   6
  Taghizade          2014   Iran          Asian                     Leiomyoma     HB               PCR-RFLP          78     133       65    276     50     74     33     157    0.563   7
  Cao                2014   China         Asian                     Breast        HB               PCR-RFLP          70     109       42    221     79     124    49     252    0.978   7
  Lu                 2015   Japan         Asian                     Prostate      HB               TaqMan            67     191       94    352     80     175    97     352    0.949   7
  Nyante             2015   USA           Caucasian                 Breast        PB               PCR               518    984       470   1972    469    908    398    1775   0.297   11
  Han                2017   China         Asian                     Prostate      HB               PCR               94     102       48    244     92     112    28     232    0.492   8

**Abbreviations:** HB, hospital based; PB, population based; PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism; HCC, hepatocarcinoma; AML, acute myeloid leukemia; HWE, Hardy-Weinberg equilibrium.

###### 

Meta-analysis of the association between *ESR1* PvuII polymorphism and cancer risk

  Variables                No. of studies   Homozygous                          Heterozygous                        Allele                 
  ------------------------ ---------------- ---------------------- --------- -- ---------------------- --------- -- ---------------------- ---------
                                            TT vs. CC                           TT vs. CT                           T vs. C                
                                            OR (95% CI)            P ^het^      OR (95% CI)            P ^het^      OR (95% CI)            P ^het^
  All                      80               0.92 (0.84-1.01)       \<0.001      0.94 (0.88-1.001)      \<0.001      **0.95 (0.91-0.99)**   \<0.001
  Cancer type                                                                                                                              
  Breast                   28               1.08 (0.98-1.19)       0.001        1.01 (0.94-1.08)       0.015        1.03 (0.99-1.08)       0.004
  Prostate                 26               **0.79 (0.66-0.94)**   \<0.001      0.89 (0.78-1.01)       0.006        **0.89 (0.82-0.98)**   \<0.001
  Leiomyoma                11               0.72 (0.49-1.06)       0.016        0.83 (0.61-1.12)       0.003        **0.82 (0.68-0.98)**   0.006
  HCC                      3                **0.45 (0.28-0.71)**   0.353        0.63 (0.39-1.04)       0.191        **0.67 (0.47-0.95)**   0.145
  Endometrial              3                0.73 (0.43-1.24)       0.067        0.73 (0.40-1.35)       0.005        0.84 (0.63-1.11)       0.046
  Others                   9                1.26 (0.85-1.90)       0.070        1.06 (0.88-1.40)       0.203        1.06 (0.88-1.28)       0.042
  Ethnicity                                                                                                                                
  Asian                    38               0.94 (0.80-1.10)       \<0.001      0.93 (0.84-1.04)       \<0.001      0.96 (0.89-1.03)       \<0.001
  Caucasian                36               0.93 (0.83-1.04)       \<0.001      0.95 (0.88-1.04)       0.003        0.96 (0.90-1.01)       \<0.001
  African                  3                **0.54 (0.30-0.98)**   0.292        0.83 (0.52-1.32)       0.870        0.70 (0.49-1.001)      0.185
  Hispanics                1                0.39 (0.11-1.34)       \-           **0.41 (0.17-0.99)**   \-           **0.55 (0.30-0.99)**   \-
  Non-Hispanic Caucasian   1                1.09 (0.81-1.47)       \-           1.04 (0.81-1.34)       \-           1.04 (0.90-1.21)       \-
  Hispanic Caucasian       1                1.18 (0.71-1.96)       \-           1.08 (0.75-1.55)       \-           1.08 (0.85-1.38)       \-
  Control source                                                                                                                           
  HB                       44               1.02 (0.91-1.13)       \<0.001      0.99 (0.92-1.08)       0.009        **0.89 (0.83-0.96)**   \<0.001
  PB                       36               **0.81 (0.70-0.94)**   \<0.001      **0.86 (0.78-0.96)**   \<0.001      0.99 (0.95-1.05)       \<0.001
  HWE                                                                                                                                      
  \>0.05                   74               0.94 (0.86-1.02)       \<0.001      **0.94 (0.88-1.00)**   \<0.001      0.96 (0.92-1.001)      \<0.001
  ≤0.05                    6                0.74 (0.33-1.67)       \<0.001      0.98 (0.80-1.21)       0.672        0.90 (0.70-1.14)       0.009
  Quality score                                                                                                                            
  \>9                      17               1.07 (0.92-1.23)       0.386        1.04 (0.98-1.11)       0.327        1.03 (0.96-1.10)       \<0.001
  ≤9                       63               **0.86 (0.77-0.96)**   0.008        **0.88 (0.81-0.96)**   \<0.001      **0.92 (0.87-0.97)**   \<0.001

**Abbreviations:** Het, heterogeneity; HB, hospital based; PB, population based.
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